An analysis of NHANES found aspirin's benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.

An analysis of the NIH's All of Us program finds no increased ILD risk with methotrexate in dermatomyositis.

Implementation of an artificial intelligence-enabled ECG reduced the risk of all-cause mortality within 90 days among hospitalized patients.

The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

This month in review features top psychiatry news in the pipeline, FDA approvals, and a piece for autism awareness month.

The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.

Lasso demonstrated advantages in predicting clinical remission in patients with RA treated with TNF, with a specificity of 69.9% and sensitivity of 61.7%.

People with diabetes exhibit significantly greater odds of developing carpal tunnel syndrome compared with non-diabetic individuals.

Patients placed in the intervention group reported significant improvements in gout knowledge levels over time compared with controls throughout the 24-week study period.

This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.

The second segment of a special report stresses the importance of cross-specialty collaboration with hepatology and psychiatry when treating alcohol-related liver disease.

In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.

The HCPLive Endocrinology month in review for April 2024 spotlights SURMOUNT-OSA, STEP HFpEF DM, new ACP guidelines for T2D, and more!

The decision by Eli Lilly to resubmit lebrikizumab to the FDA for adults and adolescents with eczema is expected to receive a response in the second half of the year.

USPSTF now advises biennial breast cancer screening from age 40 to 74 years based on an evolving evidence base.

AEYE Health receives clearance for the first artificial intelligence solution to allow fully autonomous screening for diabetic retinopathy using a portable device.

Experts continue their discussion of gene therapy, highlighting safety concerns and the need for more trials and data.

Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.

Experts shift to the prospect of gene therapy in treating retinal diseases.

This segment of the latest Lungcast episode featured a discussion over the ALA’s State of the Air Report and the impacts of particle pollution.

Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.

This April 2024 month in review highlights World IBS Day, updates in the gastroenterology pipeline, ACP Internal Medicine meeting coverage, and recent IBD research.

Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.